Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma


In Partnership With:

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Abhinav Deol, MD, physician, Barbara Ann Karmanos Cancer Institute, clinical professor, Department of Oncology, Division of Hematology-Oncology, Wayne State University School of Medicine, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

A potential avenue for improving the treatment of patients with multiple myeloma is to shorten CAR T-cell infusion wait times, Deol begins. Many patients who qualify for CAR T-cell therapy, but they are unable to receive treatment due to a limited number of available manufacturing slots, he explains, resulting in an important unmet needs in this field. The approval of teclistamab-cqvy (Tecvayli) may allow some of these patients to access therapies that were not previously available, Deol emphasizes.

Another area of interest in myeloma is whether CAR T-cell therapy can be used to improve patient outcomes earlier in the disease course, Deol expands. Furthermore, there is a 6- to 8-week period between initial lymphocyte collection and when the CAR T-cell product becomes available for infusion. Despite this delay, current data suggest that many patients who have relapsed/refractory disease have no other effective treatment options. However, utilizing CAR T-cell therapy in earlier lines may promote deeper responses, longer remissions, or prolonged disease control , he explains.

Moreover, there are ongoing investigations of allogeneic CAR T cells, which are off-the-shelf and readily available for infusion as soon as the patient requires it , Deol continues. This option appears to be safe, is not associated with graft-vs-host disease, and has produced encouraging responses, he says. Through further investigation, investigators hope to develop strategies that mitigate lymphodepletion before patients receive allogenic CAR T cells, he concludes.

Related Videos
Julia S. Wong, MD
Faith E. Davies, MD
Sagar Lonial, MD, FACP
Julie Renee Brahmer, MD
Matthew Pierre Deek, MD
Bradford (Brad) S. Hoppe, MD, MPH
Michael Chuong, MD, FACRO,
Jiye Liu, MD
Mitchell Machtay, MD, associate dean, Clinical Cancer Research, professor, endowed Chair in Cancer Clinical Research, Department of Radiation Oncology, professor, Department of Medicine, Penn State College of Medicine
Related Content